Drug intelligence / Profile preview

pmmB232

Development stage: Preclinical
Lead developer: Nanjing Forestry University
Modality: Small Molecules
Administration: In Vitro (no Clinical Human Administration Route Established)

Overview

PMMB232 is a **synthetic shikonin derivative** with potent anticancer activity, specifically demonstrated against human cervical cancer (HeLa cells). Its mechanism of action involves inducing apoptosis via reduction of mitochondrial membrane potential, promoting PARP cleavage, and downregulating hypoxia-inducible factor 1-alpha (HIF-1α), thereby impairing glycolysis. PMMB232 also upregulates E-cadherin and PDH-E1α while downregulating PDK1. Docking studies suggest a direct binding to HIF-1α[1][3][7]. The compound exhibited a strong antiproliferative effect with an IC50 of 3.25 ± 0.35 μM in vitro and is proposed as a potential anticancer agent targeting tumor cell metabolism and survival[1][3][7].

Other names: PMMB232PMMB-232PMMB 232

Targets

PARP1 (Poly (adp-ribose) polymerase 1)PDK (Pyruvate dehydrogenase kinase isoform 1)HIF1A (Hypoxia-inducible factor 1-alpha)

Beyond the preview

Go deeper on pmmB232.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pmmB232.

Explore the full profile